---
title: "Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Peregrine Capital Management LLC"
description: "Peregrine Capital Management LLC increased its stake in Ultragenyx Pharmaceutical Inc. by 24.7% during Q2, now holding 148,813 shares, valued at approximately $116,000. Several other large investors a"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/213091422.md"
published_at: "2024-08-31T02:26:04.000Z"
---

# Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Peregrine Capital Management LLC

> Peregrine Capital Management LLC increased its stake in Ultragenyx Pharmaceutical Inc. by 24.7% during Q2, now holding 148,813 shares, valued at approximately $116,000. Several other large investors also adjusted their positions. Despite trading down on Friday, Ultragenyx reported a 35.7% increase in revenue year-over-year, with a quarterly EPS of -$0.52, exceeding analysts' expectations. The stock currently has a consensus rating of "Moderate Buy" with a price target averaging $43.

Peregrine Capital Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 24.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 148,813 shares of the biopharmaceutical company's stock after buying an additional 29,474 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.18% of Ultragenyx Pharmaceutical worth $6,116,000 as of its most recent SEC filing.

-   Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Several other large investors have also made changes to their positions in RARE. Headlands Technologies LLC purchased a new stake in Ultragenyx Pharmaceutical in the 1st quarter valued at $28,000. UMB Bank n.a. raised its position in Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 352 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Ultragenyx Pharmaceutical by 622.3% during the 1st quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 865 shares in the last quarter. Van ECK Associates Corp grew its stake in Ultragenyx Pharmaceutical by 34.0% during the 4th quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company's stock worth $75,000 after buying an additional 400 shares during the last quarter. Finally, International Assets Investment Management LLC grew its stake in Ultragenyx Pharmaceutical by 3,182.4% during the 4th quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company's stock worth $80,000 after buying an additional 1,623 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

## Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock traded down $0.18 on Friday, reaching $56.78. 754,442 shares of the company traded hands, compared to its average volume of 805,332. The company has a 50 day moving average of $47.29 and a 200 day moving average of $45.70. The firm has a market capitalization of $4.72 billion, a PE ratio of -7.07 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a 52 week low of $31.52 and a 52 week high of $58.73.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.64) by $0.12. The business had revenue of $147.03 million for the quarter, compared to analyst estimates of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The company's revenue was up 35.7% on a year-over-year basis. During the same quarter last year, the firm earned ($2.25) EPS. As a group, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.24 earnings per share for the current year.

## Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Wedbush raised their price target on Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a "neutral" rating in a research note on Friday, August 2nd. Robert W. Baird boosted their target price on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an "outperform" rating in a research report on Friday, May 31st. Cantor Fitzgerald boosted their target price on Ultragenyx Pharmaceutical from $115.00 to $116.00 and gave the stock an "overweight" rating in a research report on Friday, August 2nd. Canaccord Genuity Group reiterated a "buy" rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Finally, Wells Fargo & Company upped their price target on Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an "overweight" rating in a research note on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $87.43.

**Get Our Latest Report on RARE**

## Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total value of $1,003,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,243,985 shares of the company's stock, valued at $112,580,727.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Emil D. Kakkis sold 20,000 shares of the business's stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total transaction of $1,003,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,243,985 shares of the company's stock, valued at $112,580,727.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the business's stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.10, for a total transaction of $71,390.70. Following the transaction, the director now directly owns 7,248 shares of the company's stock, valued at $297,892.80. The disclosure for this sale can be found here. Insiders have sold 32,127 shares of company stock valued at $1,539,993 over the last quarter. Corporate insiders own 5.80% of the company's stock.

## About Ultragenyx Pharmaceutical

(Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

## Featured Articles

-   Five stocks we like better than Ultragenyx Pharmaceutical
-   Stock Market Sectors: What Are They and How Many Are There?
-   The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
-   How to Calculate Options Profits
-   Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
-   High Dividend REITs: Are They an Ideal Way to Diversify?
-   Five Below Stock Faces Challenges Despite Strong Revenue Growth

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

→ $25,000 into $109,616 in two months? (From WealthPress) (Ad)## Should you invest $1,000 in Ultragenyx Pharmaceutical right now?

Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.

While Ultragenyx Pharmaceutical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [RARE.US - Ultragenyx Pharma](https://longbridge.com/en/quote/RARE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eagle Health Investments LP 增加了对 Ultragenyx 制药公司 $RARE 的股票持有量 | Eagle Health Investments LP 在第三季度将其在 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) 的持股增加了 11.1%，目前持有 697,000 股，价值约为 2097  | [Link](https://longbridge.com/en/news/276212297.md) |
| Ultragenyx 在重组期间第四季度收入增长了 25% | Ultragenyx 报告称，2025 年第四季度收入增长了 25%，主要得益于 Crysvita 和 Evkeeza 的强劲销售。该公司正在进行战略重组，裁减 10% 的员工，并预计 2026 年收入将增长 8% 至 13%，目标为 7. | [Link](https://longbridge.com/en/news/275807559.md) |
| Ultragenyx 制药的盈利前景 | Ultragenyx Pharmaceutical（纳斯达克代码：RARE）将于 2026 年 2 月 12 日公布季度财报，分析师预计每股收益（EPS）为-1.18 美元。投资者对积极的指引抱有希望，尤其是在之前每股收益低于预期 0.59 | [Link](https://longbridge.com/en/news/275643282.md) |
| 战术资源公司在私募融资中筹集了 131 万美元 | 战术资源公司通过非承销私募融资约 131 万美元，发行了 207,625 股普通股，每股价格为 6.30 美元。所筹资金将用于营运资金和公司用途，并收取 10% 的现金介绍费。该发行尚待多伦多证券交易所创业板的最终批准。战术资源专注于美国制 | [Link](https://longbridge.com/en/news/273421912.md) |
| UX111 的 FDA 重新提交申请及其在首个疾病领域的潜力将如何影响 Ultragenyx 制药（RARE）的投资者 | Ultragenyx 制药已重新提交其针对 A 型 Sanfilippo 综合症的基因治疗 UX111 的生物制品许可申请，附带新的临床数据以支持其有效性和安全性。如果获得 FDA 批准，UX111 将成为该病症的首个治疗方案，预计将在 2 | [Link](https://longbridge.com/en/news/275455868.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
